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Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired disorder characterized by paroxysms of intravascular
hemolysis. A considerable part of erythrocytes in patient blood is susceptible to autologous complement activation because
of the deficiency of CD59, which is a glycosylphosphatidylinositol (GPI)-anchored protein and inhibits the formation of the
membrane attack complex (MAC) of complement. The deficiency of CD59 is derived from the inability of GPI-anchor
synthesis. Although more than 10 proteins are involved in the GPI-anchor synthesis, the mutation of only one protein, PIG-
A, causes the defect in about 200 patients with PNH who have been analyzed. The reason why only PIG-A causes the
deficiency of GPI anchor is due to the location of its gene on X chromosome. The clonal stem cell mutated with PIG-A gene
in the bone marrow loses the capability of the synthesis of GPI-anchor. The mutation of PIG-A gene alone, however, seems
to be insufficient to account for the survival of the PIG-A-deficient cells in the bone marrow. Thus, a fraction of the mutant
stem cells probably gain a survival advantage by some additional changes, either additional mutations or changes in
immunological circumstances. The release of the surviving cells into blood stream results in a clinical syndrome with
PNH. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Paroxysmal nocturnal hemoglobinuria (PNH)
was ¢rst described by William Gull [1] in 1866 and
by Paul Strubing [2] in 1882. This disease is an ac-
quired disorder characterized by paroxysms of intra-
vascular hemolysis. A considerable part of erythro-
cytes in patient blood are highly sensitive to
autologous complement activation [3,4]. The sensitiv-
ity of erythrocytes to complement is distinctly
diagnosed by Ham’s test (acidi¢ed serum lysis test)
[5].
PNH is a rare disease at a frequency of about one
patient per 100 000 individuals; no di¡erence in the
frequency is observed between male and female. It is
generally thought that PNH is more common in
Asian countries. The ¢rst onset of PNH is observed
ranging from juveniles to elderly at the mean age of
about 40. Many of the patients with PNH survive
more than 10 years after the ¢rst onset of PNH.
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Clinical features of PNH are the intravascular he-
molysis that occasionally causes hemoglobinuria and
iron-de¢cient anemia, aplastic anemia, leukopenia,
thrombosis, hemorrhage, and leukemia at a lower
frequency. Although no e¡ective therapy for PNH
has been developed yet, the biochemical understand-
ing about PNH has progressed profoundly in recent
years. It is now evident that PNH is derived from the
de¢ciency of glycosylphosphatidylinositol (GPI)-
anchored proteins, which is due to the acquired mu-
tation of PIG-A gene resulting in the de¢ciency of
PIG-A protein.
Excellent recent reviews of pathological features of
PNH [6] and biosynthesis of GPI-anchor molecule [7]
are available. I also reviewed the same subject in
1996 [8]. This review will focus mainly on the recent
progress on biochemical background of PNH.
2. De¢ciency of glycosylphosphatidylinositol-anchored
proteins in PNH blood cells
Auditore and Hartmann [9] reported in 1960 that
the activity of acetylcholinesterase in PNH erythro-
cytes was signi¢cantly decreased. Although this ¢nd-
ing has been con¢rmed later on, the patients with an
inherited de¢ciency of acetylcholinesterase do not
su¡er from PNH, indicating that the decrease is a
secondary e¡ect. Lewis and Dacie [10] then found
in 1965 that alkaline phosphatase was de¢cient in
granulocytes from PNH patients. This de¢ciency
was also con¢rmed and unrelated to any clinical
presentations of PNH.
A breakthrough for molecular pathology of PNH
came from the works of Ikezawa et al. [11] and Low
[12]. They found that alkaline phosphatase was re-
leased from rat kidney slices by a treatment with
phosphatidylinositol-speci¢c phospholipase C (PI-
PLC). The reports led to the discovery of a new
family of membrane proteins designated GPI-an-
chored proteins. Shortly after the discovery, it was
found that acetylcholinesterase also belongs to the
GPI-anchored protein family.
The GPI-anchored protein causing the clinical
symptoms of PNH was ¢rst reported by Nicholson-
Weller et al. [13] and Pangburn et al. [14]. They iso-
lated decay-accelerating factor (DAF, CD55) from
erythrocyte membrane, which inhibited C3 conver-
tase of complement pathway. Subsequently, Nichol-
son-Weller et al. [15] found that DAF was de¢cient
in the blood cells obtained from PNH patients. The
de¢ciency explained the weakness of PNH erythro-
cytes against the complement attack. The discovery
by Davitz et al. [16] and Medof et al. [17] in 1986
that DAF was a GPI-anchored protein uncovered
the mystery why acetylcholinesterase and alkaline
phosphatase are de¢cient in PNH erythrocytes.
Thus, these ¢ndings suggest that the underlying eti-
ology of PNH might be due to the inability of GPI-
anchor synthesis.
3. Molecular characteristics of GPI-anchored proteins
The ¢nding that the de¢ciency of GPI-anchored
proteins causes PNH led us to characterize the mo-
lecular structures of GPI-anchor. Because of a lim-
ited availability of mammalian-originated GPI-an-
chored proteins, a fundamental structure of the
GPI-anchor was determined by using variant surface
glycoprotein (VSG) of Trypanosoma brucei [19]. The
GPI-anchor structure from mammalian origins is a
considerable modi¢cation of the VSG GPI-anchor.
A typical structure of the GPI anchor of human
erythrocyte membrane is shown in Fig. 1. A back-
bone of the GPI anchor consists of a phosphatidyl-
inositol, a glucosamine, three mannoses, a phospho-
rylethanolamine and a polypeptide chain. The C-1
position of glycerol binds to the alkyl chain by an
alkoxy ether bond [20] while that of VSG binds to
fatty acid by acyl linkage. The C-2 position of glyc-
erol binds to a highly unsaturated fatty acid such as
arachidonic acid by acyl linkage. One more fatty
acid, usually palmitic acid, is bound to the C-2 posi-
tion of inositol [21]. This structure renders the GPI
anchor resistant against PI-PLC prepared from bac-
teria such as Bacillus thuringens [11] and Staphylo-
coccus aureus [12]. Therefore, the resistance against
PI-PLC does not necessarily mean the absence of
GPI-anchored proteins in mammalian cells.
The core oligosaccharide structure of the GPI an-
chor is ManK1-2 ManK1-6ManK1-4 GlcNK1-6 Inos-
itol. Interestingly, the glycosidic linkages found in
GPI-anchor molecule are all K-linkages. The hydrox-
yl group at C-2 of mannose residue M1 that is linked
to glucosamine is usually occupied with phospho-
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ethanolamine that is not coupled to a polypeptide
chain. The hydroxyl group at C-4 of M1 is occasion-
ally attached to N-acetylgalactosamine or oligosac-
charide [19]. One more carbohydrate unit composed
of mannose may be found at the hydroxyl group at
C-2 of M3; the modifying enzyme is especially abun-
dant in yeast Golgi apparatus [23]. The carboxy-
terminus of polypeptide chain is attached by amide
linkage to the amino group of ethanolamine, the
hydroxyl group of which is linked via phospho-
diester bridge to C-6 of the third core mannose M3
[24].
Mammalian GPI-anchored proteins are located at
the outside lea£et of lipid bilayer of plasma mem-
brane. The molecules bind hydrophobically by three
alkyl chains to the lipid bilayer: one chain is bound
to inositol and two chains are bound to glycerol. The
palmitate bound to the hydroxyl group at C-2 of
inositol by acyl linkage might inhibit a free rotation
of inositol moiety. The free amino group of glucos-
Fig. 1. A typical GPI-anchor structure in human erythrocytes. GALNAC and MANNOSE mean N-acetyl galactosamine and man-
nose, respectively. Waved lines indicate alkyl chains.
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amine probably makes an ionic bond with the phos-
phate of PI, suggesting a rigid conformation of GPI-
anchor molecule. GPI molecules bearing no polypep-
tide have been observed in plasma membrane [25].
Those molecules are also located at the outside lea£et
of plasma membrane, in amounts severalfold more
than GPI-anchored proteins, and less than sphingo-
glycolipids. The functions of those GPIs are present-
ly uncertain.
4. Biosynthesis of GPI anchor
GPI-anchored proteins are found in almost all eu-
karyotes from yeast to mammalian. The GPI anchor
is assembled in ER, and attached to the carboxy-
terminus of polypeptide precursor (Fig. 2). Biosyn-
thesis of the GPI anchor starts at the cytoplasmic
side of ER [26] and completes at the lumenal side
of Golgi apparatus. For the elucidation of the path-
way of the biosynthesis, the cultured cell clones that
were disabled for GPI anchor biosynthesis were quite
useful. The clones produced by conventional muta-
tion techniques could be mutated in a distinct gene,
which results in the de¢ciency of the respective pro-
tein. Thus, after two de¢cient clones are fused, if the
fused cells recover the ability of GPI anchor biosyn-
thesis, the original clones are defective in di¡erent
genes, so that the fused cells recover a complete set
of genes necessary for GPI anchor biosynthesis. Us-
ing this powerful technique, called the complementa-
tion test, we can speculate how many genes are in-
volved in the GPI anchor biosynthesis. More than
10 classes have been identi¢ed so far.
Fig. 2. Biosynthesis of GPI-anchored proteins. Hexagon, rectangle and circle indicate inositol, glucosamine and mannose, respectively.
Each step indicates as follows: 1, the addition of GlcNAc; 2, deacetylation; 3, palmitoylation; 4, £ip; 5, the addition of mannose
M1; 6, the addition of EtN-P at M1; 7, the addition of mannose M2; 8, the addition of mannose M3; 9, the addition of EtN-P at
M3; 10, the cleavage of carboxy signal peptide and binding of the processed polypeptide chain.
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4.1. Addition of GlcNAc to PI
The initial step of GPI-anchor biosynthesis con-
cerns with the addition of N-acetylglucosamine
(GlcNAc) to the hydroxyl group at C-6 of inositol
residue by the action of glycosyl transferase that uses
UDP-GlcNAc as the substrate. Three di¡erent
classes of cell clones, class A, C, and H are respon-
sible for the initial step [27,28]. The genes de¢cient in
class A, C, and H clones have been cloned and des-
ignated PIG-A, PIG-C, and PIG-H, respectively. In
yeast, three genes relating with the initial step are
known as gpi1, gpi2, and gpi3 [29]. The proteins,
PIG-A and PIG-C, are homologous to the proteins,
gpi3 and gpi2, respectively. On the other hand, PIG-
H is not the homologue of gpi1. The human homo-
logue of gpi1, namely hgpi1, has recently been cloned
[30,31]. Therefore, at least four proteins are involved
in the initial step.
PIG-A is an ER transmembrane protein composed
of 484 amino acids, which shows low homology to
bacterial GlcNAc transferase [28]. PIG-A functions
at the cytoplasmic side, because the major portion of
the protein molecule is exposed at the cytoplasmic
side. PIG-H is a small protein composed of 188 ami-
no acids and belongs to a non-transmembrane type.
The major portion of PIG-H is located at the cyto-
plasmic side of ER membrane [32], and forms a com-
plex with PIG-A [18]. PIG-C consists of 269 amino
acids, which is highly hydrophobic, and has 6 or 7
transmembrane domains [33]. Thus, PIG-C might
recognize the hydrophobic region of GPI anchor.
The fourth member, hgpi1, consisting of 589 amino
acids is likely to be a transmembrane protein [30].
When ER membrane is extracted with digitoxin, all
four proteins fractionate as a complex, indicating
that those proteins form a complex on ER mem-
brane. The enzyme of the initial step shows high
substrate speci¢city, because the enzyme recognizes
the fatty acid structure of PI: bovine liver PI is a
good substrate while soybean PI is not. Thus, the
enzyme can recognize not only GlcNAc and inositol,
but also hydrophobic region such as fatty acids.
4.2. Deacetylation of GlcNAc-PI
The second step of GPI synthesis is the deacetyla-
tion of GlcNAc residue. The most likely candidate
for deacetylase is PIG-L, which is an ER membrane
protein consisting of 252 amino acids [34]. A large
part of PIG-L molecule is located at the cytoplasmic
side. The topology of PIG-L molecule is consistent
with the ¢nding that the deacetylation step proceeds
at the cytoplasmic side.
4.3. Addition of palmitate to inositol of GlcN-PI
In mammals, the third step is likely to be palmi-
toylation of the hydroxyl group at C-2 of inositol
moiety, because the palmitoylation is required for
the addition of mannose residue [7]. The acyl trans-
ferase responsible for this step has not been identi-
¢ed.
4.4. Addition of mannose residues to GlcN-(acyl) PI
Three mannoses are sequentially transferred to the
corresponding precursors by mannosyl transferases,
all of which use Dol-P-Man as the substrate. The
precise biochemical mechanism of this step remains
to be elucidated. The substrate, GlcN-(acyl) PI, is
accumulated in three mutant cell lines; Lc15, Lec35
[35] and class E. Thus, these mutant cells are defec-
tive in the addition of the ¢rst mannose residue to
GlcN-(acyl) PI. Surprisingly, these mutant cells have
distinct mutations. PIG-E protein encoded by the
DPM1 gene is dolichol phosphate-mannose (DPM)
synthase and has no membrane-binding region [37]:
it should be noted that yeast DPM synthase has the
membrane-binding region. This enzyme produces
Dol-P-Man from GDP-Man and Dol-P at the cyto-
plasmic side of ER membrane. Lec35 cells are defec-
tive in SL15, which is an ER membrane protein of 26
kDa with two spans of membrane binding region
[36]. Lec15 cells are defective in an ER membrane
protein, DPM2, which is a small hydrophobic poly-
peptide with two spans of membrane spanning re-
gion [38,39]. DPM2 associates with DPM synthase
on ER, and binds to Dol-P-Man, a mannose donor.
Dol-P-Man produced at the cytoplasmic side of
ER membrane must be transported into the lumenal
side of ER for the GPI-anchor synthesis. Thus, a
putative enzyme, £ipase, is required for the translo-
cation of Dol-P-Man into the lumenal side of ER.
Furthermore, since the deacetylation of GlcNAc-PI
proceeds at the cytoplasmic side, another substrate,
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GlcN-(acyl) PI also £ips from the cytoplasmic side to
the lumenal side, indicating the presence of another
£ipase. Presently, it is unclear whether SL15 has the
£ipase activity.
The key enzyme, mannosyl transferase for the pro-
duction of Man-GlcN-(acyl)-PI, has not been identi-
¢ed. PIG-B is a putative mannosyl transferase and
functions for the addition of the third mannose M3,
because class B mutant cells accumulate the inter-
mediate having two mannose residues. A large por-
tion of PIG-B molecule is located at the lumenal
side: The enzyme reaction should proceed at the lu-
menal side [40].
4.5. Addition of EtN-P
In mammalian cells two or three EtN-Ps are added
to mannose residues. Class F mutant cells accumu-
late the precursor that has no EtN-P on the hydroxyl
group at C-6 of M3, indicating that PIG-F might be
the EtN-P transferase [41]. Interestingly the precur-
sor accumulated in the class F clone has no EtN-P
on the hydroxyl group at C-2 of M1, indicating that
there is another EtN-P transferase. The third EtN-P
residue is occasionally found at M2. A polypeptide
chain of GPI-anchored protein is linked to the only
EtN-P residue at M3. PIG-F is a hydrophobic ER
membrane protein of 219 amino acid residues, and
phosphatidylethanolamine (PE) is the most likely do-
nor of EtN-P.
4.6. Binding of GPI anchor to polypeptide precursor
Polypeptide precursors of GPI-anchored proteins
have two signal sequences. The signal sequence at the
amino-terminal portion is required for the transport
of precursors from the cytoplasmic side to the lume-
nal side of ER membrane. On the other hand, the
signal sequence at the carboxy-terminal portion is
required for linking the precursor to GPI anchor.
The carboxy-terminal signal sequence has a certain
critical structure [42]. The carboxy-terminus of a ma-
ture GPI-anchored protein is called an g site. Thus,
the precursor polypeptide is cleaved at a peptide
bond between the g site and the g+1 site, and sub-
sequently coupled to ethanolamine of GPI-anchor.
The small amino acids like Gly, Ala, Ser, Asn, Asp
and Cys occupy the g site while a large and charged
one are observed at the g+1 site. After a spacer of 5^
10 amino acids, a hydrophobic stretch of 10^15 ami-
no acids follows: the length of the hydrophobic
stretch is insu⁄cient for the formation of a trans-
membrane structure.
Transamidase is probably involved in this step
[43]. In yeast, two genes, gaa1 and gpi8, are the can-
didates for this step. The protein gpi8 of yeast en-
codes an ER membrane protein, which shows a low
homology to a plant transpeptidase. A human homo-
logue of gaa1 protein is a putative membrane pro-
tein, a large part of which is located at the lumenal
side on ER membrane. Recently class K mutant cells
have been reported to be defective in the homologue
of gpi8 [7].
Based on those reports, we can reasonably con-
clude that at least two kinds of proteins are necessary
for the coupling of a GPI anchor to a polypeptide.
Probably one of those proteins retains the carboxy-
terminus of a polypeptide intermediate as an active
ester such as thiol ester after the cleavage between
the g site and the g+1 site.
4.7. Transport of the GPI-anchored proteins to cell
surface
GPI-anchored proteins are transferred to a Golgi
compartment where another saccharide like GalNAc
or Gal could be added as a side chain to the man-
nose residue M1. In addition, the change of acyl to
ether bond at C1 of glycerol portion proceeds before
the release from Golgi compartment. The reaction
mechanism of this step has not been elucidated yet.
In Trypanosomes two fatty acids are replaced with
short-chain fatty acids, myristic acids, at a late stage
of GPI-anchor synthesis.
A further step is known in yeast [44,45]. Several
kinds of GPI-anchored proteins are translocated to
cell wall glycan. Since mammalian cells have no cell
wall glycan, the respective reaction does not occur in
mammalian cells.
5. Cellular localization
More than 80 mammalian proteins are known to
be GPI-anchored proteins. Where are these proteins
located in cells? First, these proteins are located at a
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cell surface side on plasma membrane and at a lume-
nal side on ER membrane, and mainly function at
the cell surface. Second, these proteins are bound to
an outer lea£et of lipid bilayer via the alkyl moieties
of the GPI anchor by hydrophobic force. Therefore,
the GPI-anchored proteins cannot directly signal
through their conformational changes to the cyto-
plasmic side of plasma membrane. Third, these pro-
teins are usually located at an apical side and not at
a basolateral side of epithelial cell.
5.1. GPI-anchored proteins reside in speci¢c
patch-like structures at cell surface
GPI-anchored proteins reside in patch-like struc-
tures at cell surface, which are called ‘rafts’ [46], ‘mi-
crodomains’ [47], or ‘detergent-resistant membrane
domains (DRM)’. The rafts are smaller than 70 nm
in diameter, and cholesterol is essential to keep the
close-packed structure. Caveolae are also known to
be a patch-like structure, occasionally forming a
cave-like form, and changing to a speci¢c vesicle
which contains no clathrin. Both the rafts and cav-
eolae are rich in cholesterol and sphingolipid, which
are preferentially located at an outer lea£et of plas-
ma membrane. These lipids render a high resistance
against solubilization with nonionic detergents.
However, there are accumulating ¢ndings that there
is no enrichment of GPI-anchored proteins in the
caveolae that contain a transmembrane protein, cav-
eolin [46].
DRM associates with non-receptor-type tyrosine
kinases such as Src family, which are also bound to
the cytoplasmic side of caveolae; Src family is non-
covalently linked to lipid bilayer by their amino-ter-
minal myristoylation. The driving force clustering
these molecules into DRM seems to be a closely
packed structure formed with saturated fatty acids.
Signal transduction mechanisms via GPI-anchored
proteins are of interest. The crosslinking of CD59
with an anti-CD59 antibody activates Src family to
phosphorylate cellular proteins, signaling the activa-
tion of cells such as T lymphocyte [48]. The involve-
ment of ankyrin, a membrane skeleton protein, but
not clathrin, has been reported [49]. Although the
lipid composition of the inner lea£et of these
patch-like structures is unclear, the supplement of
polyunsaturated fatty acids in the culture medium
inhibited the activation of T cells, supposedly due
to disruption of these structures [50].
5.2. Degradation of GPI-anchored proteins
Degradation pathway of GPI-anchored proteins in
mammalian cells remains to be solved. Although the
activity of PI-PLC can be observed in mammalian
tissues, the responsive molecule has not been identi-
¢ed, and appears to be distinct from bacterial en-
zymes. Mammalian tissues appear to ubiquitously
contain phosphatidylinositol-speci¢c phospholipase
D (PI-PLD), and blood especially shows a high en-
zymatic activity [51,52]. This enzyme can cleave the
palmitate-substituted GPI-anchor. However, PI-PLD
cleaves almost no GPI-anchored proteins on intact
membrane while it does cleave their detergent-solu-
bilized form. Recently, GPI-PLD has been reported
to intracellularly cleave GPI-anchored proteins well ;
this enzyme is speci¢c for GPI-anchor and does not
cleave phosphatidylinositol [53,54]. Since the urinary
form of CD59 has an inositol moiety at the tail, the
major degradation pathway seems to be the cleavage
at GPI-anchor portion and not proteolytic cleavage
[22].
GPI-anchored receptors such as folate receptor re-
cycle between cell surface and an internalized vesicle,
so called potocyte, after the corresponding ligands
are bound. Subsequently the potocyte is acidi¢ed to
release the ligands from the receptor [55]. There is
con£icting interpretation of the recycling mechanism
of potocyte. Thus, Mayer et al. [56] have postulated
that GPI-anchored proteins were not enriched in po-
tocytes but internalized in endosomes, and that GPI-
anchored proteins were more rapidly recycled than
transmembrane proteins: cholesterol facilitated the
recycling rate.
Functions of the GPI anchor might be di¡erent
between microorganisms like yeast and mammals
like human, because the GPI anchor is essential for
the growth of yeast but not essential for that of
mammalian cells. In yeast cells, GPI-anchored pro-
teins are involved in the intracellular transport of cell
wall component [45]. Thus, the de¢ciency of GPI
anchor causes the disruption of cell wall, so that
the a¡ected cells are hard to keep alive. In mamma-
lian cells, the cells lacking GPI-anchor normally
grow on cell culture. Since the PIG-A knockout
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mice, however, are lethal at embryonic stages, the
GPI-anchor is essential for their lives [57]. A condi-
tional knockout mouse was produced by Cre-loxP
recombination technique [58]. When only the PIG-
A gene in the skin of this mouse is disrupted while
the gene in all other tissues is normal, the mouse died
within a few days after birth by dysfunction of skin:
the a¡ected skin showed quite abnormal structures.
These ¢ndings indicate that GPI-anchor expression is
essential for tissue development.
6. Somatic mutation of PIG-A gene is a main cause of
PNH
PNH arises through a somatic mutation of the
PIG-A gene in bone marrow stem cells. To date,
mutations of PIG-A have been observed in all of
the more than 200 PNH patients examined. Why
does the PIG-A gene alone cause the disease while
more than ten kinds of proteins are required for the
synthesis of GPI-anchor molecules? A reasonable
answer is that the PIG-A gene alone locates on X
chromosome while all other genes necessary for the
synthesis of GPI-anchor locate on autosomal chro-
mosome [7]. Since males have only one X chromo-
some, the inactivation of a gene located on the X
chromosome causes a complete loss of the gene prod-
uct. In females who have a pair of X-chromosomes,
since either X chromosome in a somatic cell can be
inactivated by lyonization, the gene product on the X
chromosome is produced from a single gene even in
females. Thus, the susceptibility to somatic mutation
on X chromosome is the same between males and
females. On the other hand, every autosomal chro-
mosome is present as a pair and usually the gene
products from the paired chromosome are evenly
produced from each gene. Thus the inactivation of
two genes is required for the complete loss of the
gene products: complete loss is quite rare.
A di¡erence between somatic and hereditary mu-
tation should be brie£y mentioned for understanding
the etiology of PNH. In hereditary disorder of an X
chromosomal gene, the a¡ected males do not pro-
duce the mutated gene product at all, and are con-
sequently susceptible to the disorder. Although, in
the a¡ected females, half of the cells do not produce
the mutated gene product because either X gene is
inactivated by lyonization, the other half do produce
the gene product and proliferate normally. There-
fore, females are much more resistant to hereditary
disorder due to the mutation of the X chromosome
than males. However, in somatic mutation, only the
cells evolved from a mutated cell are a¡ected. The
a¡ected individuals have a large part of normal cells
and a small part of the a¡ected cells. Although the
cells mutated disadvantageously for survival cannot
proliferate, the mutated cells occupy only a tiny part
compared with normal cells. In consequence, the
elimination of the mutated cells does not a¡ect the
life of the whole body.
Although PIG-A-de¢cient cells would be produced
everywhere in the whole body by somatic mutation,
these cells are rapidly eliminated by autologous com-
plement activation. Therefore, the PIG-A-de¢cient
cells cannot proliferate so that the somatic mutation
of PIG-A gene is unlikely to cause a disease. As an
exceptional case, the stem cells de¢cient in PIG-A
survive in the bone marrow of PNH patients.
6.1. No hot spots on the mutation of PIG-A gene
Since PIG-A gene might have highly susceptible
positions, hot spots, for the mutation, the nucleotide
sequences of mutated PIG-A genes have been ana-
lyzed from more than 200 cases of PNH. No hot
spots have been found so far [59]. The PIG-A gene
is split into six exons, all of which can be mutated. A
large part of mutations observed are one-base-muta-
tion such as substitution, insertion and deletion,
which cause either the formation of a terminal codon
near the mutation point or altered splicing. Muta-
tions derived from insertion or deletion of a long
sequence are rarely observed.
Attention should be taken for the female patients
with PNH, because the PIG-A gene inactivated by
lyonization could be analyzed by chance: one PIG-A
gene is normal with the female patients. Since no
mutations are observed with the PIG-A gene of
healthy individuals, we can conclude that the muta-
tion is responsible for PNH. Interestingly, several
patients had multiple clones each mutated at a di¡er-
ent position in their PIG-A gene [60]. These ¢ndings
indicate that a mutation event is not so rare in so-
matic cells of the patients with PNH, or that the high
incidence of mutation may be speci¢c for PNH.
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6.2. Resistance to apoptosis of the cells de¢cient in
PIG-A
The PIG-A-de¢cient cells tend to survive in the
bone marrow of PNH patients, indicating that the
cells have acquired a survival advantage. An explan-
ation for the survival advantage is that the PIG-A-
de¢cient cells are resistant to apoptosis [61,62]. Re-
cently, the mechanism of the resistance has been an-
alyzed in detail [63]. The ¢nding that the granulo-
cytes from PNH patients are resistant to apoptosis
has been veri¢ed, but no di¡erence in apoptosis be-
tween PIG-A-de¢cient JY5 cell line and the cell line
transfected with the PIG-A gene was observed.
7. GPI-anchored proteins expressed in erythrocytes
Although it is evident that the defect of PIG-A
protein causes the onset of PNH, this ¢nding does
not explain anything about the clinical features of
PNH. Since the major symptom of PNH is hemoly-
sis, PNH erythrocytes should have a certain abnor-
mal structure responsible for the susceptibility to he-
molysis. Thus, a survey of GPI-anchored proteins
expressed in erythrocytes is important to understand
PNH. A list of GPI-anchored proteins on human
blood cells is shown in Table 1, and those found in
human erythrocyte membrane are shown in Table 2.
7.1. Acetylcholinesterase
Erythrocytes alone among blood cells contain ace-
tylcholinesterase. The catalytic subunit is bound to
the proline-rich attachment subunit having GPI-an-
chor [64]. Patients with inherited de¢ciency of acetyl-
cholinesterase do not develop PNH presentation, in-
dicating that the de¢ciency is a secondary e¡ect in
PNH.
7.2. LFA3 (CD58)
This molecule belongs to immunoglobulin super-
gene family, and plays a role in cell adhesion as a
ligand for CD2. LFA3 is highly expressed in lympho-
cytes, and much less in erythrocytes. LFA3 is known
to have two forms by splicing di¡erence, GPI-an-
chored form and transmembrane form [65]. Since
no hereditary de¢ciency of CD58 has been reported
as yet, the contribution of LFA3 de¢ciency on the
clinical features of PNH is unclear.
Table 2
GPI-anchored proteins found in human erythrocyte membrane
Name Mr (kDa) Molecules/cella Blood group
CD59 20 30 000
CD55(DAF) 70 3000 Cr, Inab
CD58(LFA3) 60 3000
CDw108 76 3000 JMH
Acetylcholinesterase 72 500 Yt
aMolecules/cell indicate approximate numbers of molecules per erythrocyte.
Table 1
GPI proteins found in human blood cells
Protein E L G P M
DAF (CD55) + + + + +
LFA-3 (CD58) + + + 3 +
CD59 + + + + +
Acetylcholinesterase + 3 + 3 3
CDw108 (JMH antigen) + + 3 3 3
CD16 (FcRIII) + + + 3 3
Alkaline phosphatase 3 + + 3 3
CD14 3 3 3 3 +
CD24 3 + + 3 3
CD48 3 + 3 3 3
CD66b (CD67) 3 3 + + +
CD73 (5P-nucleotidase) 3 + 3 3 3
uPAR 3 3 + 3 +
The cells that do not synthesize GPI-anchored proteins could
have a trace amount of those proteins, because GPI-anchored
proteins might be transferred spontaneously from normal cells
to the de¢cient cells. E, erythrocyte; L, lymphocyte; G, granu-
locyte; P, platelet ; M, monocyte; +, present; 3, absent.
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7.3. CDw108 (JMH blood group antigen)
CDw108 antigen belongs to a family of cell adhe-
sion molecule of Mr 80 kDa, one of the lymphocyte
activation markers. Recently Murad et al. [66] has
reported that this protein bears the JMH blood
group antigen. The absence of Cdw108 appears to
be a secondary e¡ect, because JMH-minus erythro-
cytes are apparently normal.
7.4. DAF (CD55)
DAF accelerates the decay of C3 convertases,
C4aC2a and C3bBb, of complement pathway [13].
DAF bears Cromer-blood-group antigen, Cra: the
complete defect of Cra antigen is called Inab [67].
The individuals showing Inab blood group appear
to be healthy. Because there are alternative inhibitory
factors of C3 convertase, factor H and C4BP in hu-
man plasma and CR1 in erythrocyte membrane, by-
stander activation of complement is suppressed even
in Inab individuals. The ¢ndings mentioned above
indicate that DAF is not an essential factor for the
hemolytic onset of PNH [68].
7.5. CD59
CD59 is also called p18 [69], MACIF [70], MIRL
[71], MEM43 [72], H19 [73], HRF20 [74], and pro-
tectin [75]. This small protein of about 18 kDa in-
hibits the MAC-formation of complement. A male
with an inherited defect of CD59 reported by Yama-
shina et al. [76] had single nucleotide deletions in
codon 16 (GCC to GC) and codon 96 (GCA to
CA), probably either one mutation in each allelic
chromosome, in CD59 gene. The deletion in codon
16 resulted in a frameshift to introduce a stop codon
at codon 54. The survey of the family genetics indi-
cated that the mutations were hereditary, supporting
that the mutation of CD59 gene is inheritable. The
patient exerted hemolytic anemia, thrombosis caus-
ing cerebral infarction, and several other features of
PNH. The ¢ndings obtained from the patient indi-
cate that the de¢ciency of CD59 is the major cause of
the susceptibility to hemolysis by autologous comple-
ment activation.
CD59 was ¢rst isolated from human erythrocyte
membrane in 1988 [69] and is widely expressed in
human cells as a complement inhibitor working at
Fig. 3. Reaction mechanism of CD59. CD59 binds to C5b-8 and C5b-9 to inhibit the formation of membrane attack complex of com-
plement.
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the stage of C5b-8 and C5b-9 [77] (Fig. 3). When
CD59 is absent on cell surface, C5b-9 polymerizes
about 16 molecules of C9 to form MAC, a pore-
like structure, which leads the a¡ected cells to death.
It binds to a-chain of C8 and the b-domain of C9
[78]. The mature form of CD59 consists of 77 amino
acids, and contains ¢ve disul¢de bonds: Asn18 is N-
glycosylated. CD59 loses its activity by the degrada-
tion of its disul¢de bonds with thiol reagents: the
disul¢de bonds are critical to maintain the three-di-
mensional structure. Another characteristic of CD59
is homologous restriction. Thus, human CD59 can
inhibit the activation of human complement, but
less so in non-primates such as rabbit and rat [79].
8. GPI-anchored proteins expressed in leukocytes
Clinical signi¢cance derived from the de¢ciency of
GPI-anchored proteins in leukocytes is presently in-
signi¢cant. Although about 60% of patients with
PNH su¡er from leukopenia, leukocytes of PNH pa-
tients are apparently normal and their life spans are
in normal range.
8.1. Alkaline phosphatase
The hereditary de¢ciency of this enzyme is hypo-
phosphatasia whose symptoms are dissimilar to
PNH, indicating that the de¢ciency is not essential
for PNH [80].
8.2. CD16 (FcRIII)
An individual su¡ering from recurrent viral infec-
tions since birth carried a CD16-mutated form. The
clinical features of this patient were inconsistent with
those of the patients with PNH [81].
8.3. CD24
This molecule is a 46-amino-acid peptide glycosyl-
ated heavily, and a ligand of P-lectin [82]. CD24 has
been implicated in both activation and di¡erentiation
of B lymphocyte to produce immunoglobulin. Other
hematopoietic cells do not express CD24. The pa-
tients with PNH do not indicate any signi¢cant
disorder of immunoglobulin production, indicating
that CD24 is not concerned with the symptom of
PNH.
8.4. CD48
CD48 (Blast-1) is an activation-associated cell sur-
face glycoprotein of 40^45 kDa expressed primarily
in mitogen-stimulated human T lymphocytes. It is
said that this molecule is a cell adhesion molecule
because it belongs to the immunoglobulin supergene
family. Recently, 2B4, a surface glycoprotein ex-
pressed in NK and T cells, has been reported to be
a ligand for CD48 [83].
8.5. CD52w (CAMPATH-1)
This antigen is a peptide composed of 34 amino
acids and heavily glycosylated. The antibodies
against this antigen e¡ectively activate complement,
resulting in cell lysis. This ¢nding indicates that the
cells de¢cient in CD52w should be more resistant to
complement activation than normal cells [84]. There-
fore, this molecule is not concerned with the symp-
tom of PNH.
8.6. CD66b
This molecule, which had been also called CD67,
is a subclass of immunoglobulin supergene family as
well as a subclass of CEA. Although its function
remains to be solved, the molecular structure indi-
cates a cell adhesion activity [85].
8.7. CD73
This molecule exhibits 5P-nucleotidase (NT5) activ-
ity. The enzyme is used as a marker of lymphocyte
di¡erentiation. A hereditary de¢ciency of NT5 oc-
curs in a variety of immunode¢ciency diseases unre-
lated to PNH [86].
8.8. CD87 (uPAR)
This protein is a receptor for urokinase-type plas-
minogen activator (uPA), which catalyzes the activa-
tion of plasminogen to plasmin. CD87 belongs to the
same supergene family, called Ly6 or neurotoxin
family, as CD59. The expression in vivo is associated
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predominantly with macrophages in in£ammatory
sites. Soluble CD87 is increased about 2 times in
the plasma of patients with PNH, although the
mechanism is unclear [87]. A soluble form of CD87
could inhibit the activity of uPA, resulting in the
decrease of ¢brinolysis. Since the macrophage defec-
tive in CD87 increases in the patients with PNH, the
¢brinolysis on the surface of the a¡ected cells might
decrease. Therefore, thrombosis might be caused
with the de¢ciency of this protein [88].
8.9. Arginine-speci¢c mono-ADP-ribosyltransferase
A new member of GPI-anchored protein is mainly
expressed in cytotoxic T lymphocytes, and suppresses
the T cell activation [89].
9. Clinical features and molecular pathology of PNH
PNH is classi¢ed as a hemolytic anemia because of
the intravascular hemolysis. It is also related with
aplastic anemia: the patients with aplastic anemia
occasionally su¡er from PNH and vice versa. There
is no increased incidence with families, supporting
that PNH is an acquired disorder. How can we ex-
plain these clinical features of PNH from the ¢ndings
mentioned above?
An unresolved question is how GPI-anchor-de¢-
cient cells can survive in the bone marrow while these
cells are highly susceptible to autologous comple-
ment activation. The a¡ected cells must acquire sur-
vival advantage in the bone marrow: Luzzatto et al.
[90] explain this state as ‘a blessing in disguise’. They
surmise that, without the survival advantage, pa-
tients would su¡er from aplastic anemia in which
the a¡ected cells are rapidly eliminated. If their pro-
posal is true, what is the molecular basis of the sur-
vival advantage? The inactivation of PIG-A protein
alone seems not to acquire survival advantage, be-
cause PIG-A knockout mice exhibit severe disad-
vantage in the survival of stem cells. When chimeric
mice were produced to examine the di¡erence in
growth between GPI-de¢cient cells and GPI-positive
cells, GPI-de¢cient cells were rapidly removed in the
bone marrow [56]. Therefore, although PIG-A muta-
tion is required for the development of PNH, addi-
tional factors should be acquired for the survival
advantage of PIG-A-de¢cient cells: The additional
factors could be either an additional mutation of
another gene or a change in immunological circum-
stances.
Soluble forms of GPI-anchored proteins increase
in the patients with PNH. The soluble form of CD59
obtained from urine of healthy persons contains in-
ositol and no glycerol, supporting the release with
phospholipase C or D [22]. Although the soluble
form weakly inhibits the complement activation, its
biological signi¢cance is unclear. The case of DAF is
somewhat complicated, because two cDNA clones
are identi¢ed; one is for GPI-anchored form and
the other for secreted form [91,92].
9.1. Hemolysis and hemoglobinuria
The erythrocytes obtained from PNH patients are
classi¢ed into three groups by their susceptibilities to
hemolysis; PNH I, PNH II, and PNH III, which are
normal, partially susceptible, and highly susceptible
to hemolysis by Ham’s test, respectively. Those cells
are more de¢nitely classi¢ed by £ow cytometry using
monoclonal anti-CD59 antibodies. PNH I, PNH II,
and PNH III cells contain normal, decreased, and
completely de¢cient amounts of GPI-anchored pro-
teins, respectively. Thus, the data that the suscep-
tibilities to Ham’s test are consistent with the
decreased amounts of CD59 on erythrocyte mem-
branes, con¢rm that the complement activation ac-
count for the hemolysis by Ham’s test. The ratio of
these three classes varies depending on patients; even
in the same patient the ratio changes from time to
time. More than half of the PNH patients have PNH
I and PNH III cells without PNH II cells. Even when
the patients have PNH II cells, the content of PNH
II cells is usually low. The presence of PNH II cells,
which partially produce the GPI-anchor, indicates
that the expression of GPI-anchor proteins is not
necessarily an all-or-none event.
The mutation types of phenylalanine oxidase of
patients with phenylketonuria, a typical hereditary
disease, have been accumulated over 200 types.
Some patients showed a low expression of the en-
zyme activity. In these cases, a point mutation result-
ing in amino acid substitution caused the decrease of
enzyme activity. A mutation of the promoter region
could also cause a decreased synthesis of the enzyme.
BBADIS 61873 13-9-99
M. Tomita / Biochimica et Biophysica Acta 1455 (1999) 269^286 281
The decreased synthesis of GPI-anchored proteins in
PNH II erythrocytes could be explained by a similar
mechanism. Indeed, Rollinson et al. [93] showed that
the substitution of Cys183 with Phe of PIG-A pro-
tein led to PNH II cells while the substitution of the
same site with Trp led to PNH III cells. These ¢nd-
ings also indicate that PNH II and PNH III cells are
clonally distinct.
Hemoglobinuria is occasionally observed with pa-
tients whose PNH III erythrocytes are more than
20% of total cells. Several hypotheses have been
postulated why hemoglobinuria mainly happens at
night. The onset of hemoglobinuria should be ac-
companied by the acute increase of complement ac-
tivation. Although it has been postulated that the
retention of CO2 in local blood plasma leads to a
slight fall of pH that activates complement pathways,
the avoidance of CO2 retention by the use of a
Drinker respirator failed to prevent the nocturnal
hemoglobinuria. The most likely assumption at
present is the increased absorption of intestine-bacte-
rial lipopolysaccharide at night, which tends to acti-
vate complement pathway [94]. In rare cases PNH
patients evolve renal disorder. Conceivably, hemo-
globin in plasma would be harmful to kidneys [95].
9.2. Iron-de¢cient anemia and aplastic anemia
Patients with PNH are commonly iron-de¢cient
because of the increased loss of iron in urine during
intravascular hemolysis, i.e., hemosiderinuria. The
hemoglobin concentration of the patients is often
less than 6 g/dl of blood. About 20% of patients
with PNH had aplastic anemia prior to the develop-
ment of PNH. The decrease of proliferation of bone
marrow stem cells leads to aplastic anemia. It is well
known that the patients with aplastic anemia had a
10^100-fold increase of blood erythropoietin concen-
tration. A similar increase of erythropoietin is ob-
served in PNH patients [96].
9.3. Leukopenia
About 60% of patients with PNH su¡er from leu-
kopenia. The leukopenia could derive from two rea-
sons: aplastic anemia and the shortened life span of
a certain group of leukocytes. The de¢ciency of GPI-
anchored proteins has been analyzed for granulo-
cytes. In most cases, the proportion of de¢cient cells
was parallel between granulocytes and erythrocytes.
The leukocytes lacking CD59 are considerably resist-
ant against autologous complement activation, hav-
ing an almost normal life span, whereas the CD59-
de¢cient erythrocytes have a quite short life span,
putatively about 10 days for PNH III cells.
The life span of blood cells a¡ects the ratio of the
GPI-anchor-de¢cient cells in blood. Granulocytes
live about 2 weeks while erythrocytes live about
160 days. Therefore, the de¢cient granulocytes in-
crease more rapidly than the de¢cient erythrocytes
when the de¢cient stem cells increase. Since lympho-
cytes can grow outside the bone marrow, the increase
of the de¢cient lymphocytes does not mirror the in-
crease of the de¢cient stem cells. The proportion of
the a¡ected lymphocytes is generally less than that of
the de¢cient granulocytes. Lymphocyte subsets are
highly variable among patients, although NK cells
tend to be much less [97].
9.4. Thrombosis and hemorrhage
Normal platelets have a number of GPI-anchored
proteins such as CD55 and CD59. The GPI-anchor-
de¢cient platelets are found in blood of the patients
with PNH. The a¡ected platelets seem to be very
susceptible to complement activation: hence, the af-
fected platelets are always observed at a low level in
blood, useless for the diagnosis of development of
PNH. The decrease of platelets should cause bleeding
tendency. However, more than half of patients with
PNH tend to have thrombosis, indicating that the
increase of degrading platelets activate blood coagu-
lation.
Thrombosis may occur in hepatic veins (Budd^
Chiari syndrome) and also in portal, splenic, cere-
bral, and other veins and account for about 50% of
all the fatal onsets on the patients with PNH in the
United States [6]. Especially, most patients who suf-
fer from hepatic venous thrombosis may die within a
few months. However, it must be noted that hemor-
rhage with fatal bleeding in cerebral or gastrointesti-
nal organs is a most frequent cause of all the deaths
in Japanese patients with PNH [98]. The di¡erence
appears to depend on the race because the cases of
Asian patients are similar to those of Japanese pa-
tients. Additionally, Japanese ingest much ¢sh rich in
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polyunsaturated fatty acids, which is known as a
preservative against thrombosis. Consequently, Jap-
anese have a tendency to hemorrhage rather than
thrombosis. Therefore, this dietetic habit might cause
the diversity in fatal onset between Japanese and
Americans.
9.5. Leukemia and myelodysplastic syndromes
(MDS)
About 2% of the patients with PNH develop acute
myeloblastic leukemia (AML). Therefore, PNH can
be regarded as a preleukemic stage. GPI-anchored
proteins are also de¢cient in the evolved leukemia
cells, indicating that the leukemia cells evolved
from the PIG-A-de¢cient stem cells. A considerable
portion of PNH patients with complication of leuko-
penia shows myelodysplastic syndromes (MDS).
These patients may have a high risk to evolve leuke-
mia, because these patients clearly have additional
mutations other than the mutation of PIG-A gene,
so that a risk of leukemia is likely to emerge. A
putative gene mutated in the PNH patients with
MDS is p15NK4B [99].
10. Treatment of PNH
Many patients are just under observation without
any special treatments. Only under severe conditions,
the patients are treated with the therapies soothing
their conditions. Iron, folic acid and blood are given
for the treatment of anemia. For suppressing throm-
bosis, anticoagulants like heparin are e¡ective, but
daily uptake of warfarin seems to be ine⁄cient on
the inhibition of thrombosis. For the patient with
severe thrombocytopenia, therapy with platelet con-
centrates clearly improves survival from hemorrhage.
Immunosuppressive therapy, which is used for the
treatment of aplastic anemia, is generally ine¡ective
for treating PNH. However, the patients showing
seriously advanced bone marrow hypoplasia can be
improved with immunosuppressive therapy, indicat-
ing that immunological circumstances facilitate the
clinical severity of PNH.
Spontaneous recovery is occasionally observed in a
small portion of patients; in such patients, PNH cells
are absent for at least several years. The study by
Hillmen et al. [92] showed that up to 15% of patients
were spontaneously cured. Therefore, although bone
marrow transplantation can be quite e¡ective, the
transplantation should be restricted to the patients
with severe conditions such as severe hypoplasia
and reoccurring thrombosis. A prolonged study on
the PNH patients treated with bone marrow trans-
plantation has been reported [101]. Some of the pa-
tients treated with a syngeneic bone marrow trans-
plant relapsed with PNH several years after the
transplantation. Interestingly, the relapsing PNH
cells were distinct from the original PNH cells, sug-
gesting that a new PIG-A mutation happened again
in the patient.
Autologous transplantation would be a safe treat-
ment. The primitive stem cells that can di¡erentiate
into all the hematopoietic cells are classi¢ed in
CD34383 cells. A major fraction of the Cd34383
cells express CD59, even when the cells were col-
lected from the patients of severe conditions. There-
fore, if the cells can be proliferated in vitro, we can
use the proliferated cells as the source of autologous
transplant. Unfortunately, when the cells were prolif-
erated in vitro with G-CSF, the PNH cells were pref-
erentially expanded over normal cells [102].
The transfer of GPI-anchored proteins from nor-
mal cells to GPI-anchor-de¢cient cells has been ob-
served [103]. The release of GPI-anchored proteins
from membrane is much easier than that of trans-
membrane proteins. Therefore, the transfer of GPI-
anchored proteins, especially CD59, to PNH eryth-
rocytes by using an appropriate vehicle such as HDL
or microvesicles might be hopeful [104].
The prognosis of PNH patients is rather poor and
the conditions usually become severe at an interval of
several years. Several epidemic studies on the life
span of PNH patients after the onset have been re-
ported [100]. The average survival years of the pa-
tients vary from 8 years to 25 years, depending on
the study. A survey with the aid of the Ministry of
Health and Welfare of Japan demonstrated that the
average life span after the diagnosis of PNH is ap-
proximately 25 years and that the patients die at the
mean age of 50.4 [98]. The main di¡erence in the
values among those studies might come from the
di¡erence in the de¢nition of diagnosis, the consid-
eration of spontaneously cured patients and the dif-
ference in races. Further evidence that a considerable
BBADIS 61873 13-9-99
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portion of the patients seem to die of unrelated
courses with PNH makes the statistic studies more
complicated.
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